Toward Glioblastoma Treatment with High Spatiotemporal Precision: Controlling Temozolomide Release from Upconverting Nanoparticles Using Near-Infrared Light
{{output}}
As the first-line chemotherapeutic for glioblastoma multiforme (GBM), Temozolomide (TMZ) suffers from rapid degradation in physiological fluid, making it difficult to deliver sufficient doses of active TMZ to GBM tumors without inducing severe side effects. By... ...
